Heron Therapeutics Inc vs PAGSEG Inc — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $61.47M), while PAGSEG Inc trades at $8.8 (market cap $2.48B). The key difference: PAGSEG Inc is far larger — about 40.3× Heron Therapeutics Inc's market cap, and PAGSEG Inc pays a 11.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | PAGS | |
|---|---|---|
Market Cap | $61.47M | $2.48B |
Sector | Health | Technology |
52-Week High | $1.49 | $12.00 |
52-Week Low | $0.32 | $8.38 |
Enterprise Value | $168.21M | $10.22B |
Dividend Yield | — | 11.7% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
PAGS trades at $8.59, down 5.4% in the last session, with a bearish technical signal despite attractive valuation metrics (P/E 6.17, P/S 0.64). The company reported $20.41B revenue and $2.12B net income for 2025, maintaining stable profitability with a 10.4% net margin. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while analyst consensus remains bullish with a $11.45 price target.
The stock presents a value opportunity given its discounted valuation and strong analyst support (62.5% buy ratings), but faces headwinds from technical weakness and competitive pressures in Brazil's digital banking sector. Upside potential exists if earnings momentum continues, though investors should monitor execution risks and macroeconomic conditions affecting Brazilian financial markets.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →